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ORIGINAL ARTICLE
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Abstract
Background Epidermolysis bullosa (EB) is a heterogeneous group of rare and incurable genetic disorders character-
ized by fragility of the skin and mucosae, resulting in blisters and erosions. Several epidemiological studies in other pop-
ulations have been carried out, reporting varying and sometimes inconclusive figures, highlighting the need for
standardized epidemiological analyses in well-characterized cohorts.
Objectives To evaluate the epidemiological data on EB in the Netherlands, extracted from the molecularly well-charac-
terized cohort in the Dutch EB Registry.
Methods In this observational study all EB-patients that were based in the Netherlands and captured in the Dutch EB
Registry between 1988 and 2018 were included. The epidemiological outcomes were based on complete diagnostic
data (clinical features, immunofluorescence, electron microscopy and mutation analysis), with longitudinal follow-up.
Results A total of 464 EB-patients (287 families) were included. The incidence and point-prevalence of EB in the
Netherlands were 41.3 per million live births and 22.4 per million population, respectively. EB Simplex (EBS), Junctional
EB (JEB), Dystrophic EB (DEB) and Kindler EB were diagnosed in 45.7%, 18.8%, 34.7% and 0.9% of the EB-patients,
respectively, with an incidence and point-prevalence of 17.5 and 11.9 (EBS), 9.3 and 2.1 (JEB), 14.1 and 8.3 (DEB), 0.5
and 0.2 (Kindler EB). In 90.5% of the EB-patients the diagnosis was genetically confirmed. During the investigated time
period 73 EB-patients died, 72.6% of whom as a direct consequence of their EB.
Conclusion The epidemiological outcomes of EB in the Netherlands are high, attributed to a high detection rate in a
well-organized set-up, indicating that EB might be more common than previously assumed. These epidemiological data
help to understand the extensive need for (specialized) medical care of EB-patients and is invaluable for the design and
execution of therapeutic trials. This study emphasizes the importance of thorough reporting systems and registries
worldwide.




Stichting Vlinderkind (Dutch Butterfly Child foundation) has attributed to this study by financially supporting the care of
patients with epidermolysis bullosa at our centre.
Introduction
Epidermolysis bullosa (EB) is a heterogeneous group of rare and
incurable genetic cutaneous disorders, caused by mutations
within the genes encoding critical proteins for the intra-epider-
mal cell–cell adhesion and dermo-epidermal junction (DEJ).1,2
The very recent consensus classification has now divided this
heterogeneous group of skin fragility disorders in ‘classical’ EB
and ‘EB-related’ disorders.2 Depending on the level of skin cleav-
age, four major types of EB are recognized: EB Simplex (EBS),
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Junctional EB (JEB), Dystrophic EB (DEB) and Kindler EB.
Based on the clinical severity, inheritance pattern and molecular
defects, these major types of EB are further divided into many
subtypes, that share common features of mechanical fragility
and blistering of the skin and mucous membranes.1,2 Most EB-
patients have lifelong blistering and erosions with significant
morbidity due to related complications, associated with early
mortality.1
The Center for Blistering Diseases at the University Medical
Center Groningen (UMCG) in the Netherlands is a recognized
European and the only national expertise centre for EB. Since
the registration of its first patient in the Dutch EB Registry
(Dutch-EB-Reg) in 1988 the centre has evolved and contributed
to the diagnosis, research and management of EB-patients in the
Netherlands and other countries for over three decades.3
Epidemiological data improve our understanding of EB,
emphasize the extent and need for (specialized) medical care of
EB-patients and are invaluable for the design and execution of
therapeutic trials. Several epidemiological studies in other popu-
lations have been carried out, reporting varying and sometimes
inconclusive figures (incidences of 1.4–25.0 per million live
births and prevalences of 2.82–54.0 per million population),
mostly based on clinical features or molecular findings. Through
this report, we provide accurate epidemiological figures of each
subtype of EB according to the novel consensus report, including
subtype-specific mortality rates, extracted from the molecularly
well-characterized Dutch EB cohort in the Dutch-EB-Reg, estab-
lished over a 31-year period.
Materials and methods
Study design and data collection
In this population-based and observational (cross-sectional and
longitudinal) study, all EB-patients registered at our centre from
01-Jan-1988 until 31-Dec-2018 were included. EB-patients referred
to our expertise centre by specialists from foreign countries were
excluded in order to provide accurate epidemiological outcomes
of EB in the Netherlands. The diagnosis of EB was established
based on clinical features, skin biopsies for immunofluorescence
antigen mapping (IFM) and transmission electron microscopy
(TEM), and in particular mutation analysis, which over the years
evolved from sanger sequencing of single candidate genes to next-
generation sequencing of multiple EB-related genes in parallel.4
The subclassification of EB was conducted according to the latest
consensus report.2 The medical records of the EB-patients were
systematically collected during the investigated time period and
retrospectively examined. This study was carried out in accordance
with the principles of the Declaration of Helsinki.
EB-related skin fragility disorders
The 2020 EB-consensus reclassification separated the former
suprabasal EBS phenotypes as ‘EB-related skin fragility
disorders’ from the classical EB-phenotypes (acral peeling skin
syndrome, lethal acantholytic EB, skin fragility-woolly hair syn-
drome and skin fragility-ectodermal dysplasia syndrome).1,2
Therefore, patients with such phenotypes were excluded in the
calculations and described in the Appendix S1 (Supporting
Information).
Data analysis
The quantitative and qualitative characteristics of the EB-pa-
tients were summarized as absolute numbers, averages together
with standard deviations (SD) and proportions (%). Incidences
were calculated per million live births [total no. of new EB-pa-
tients born (1-Jan-1988 until 31-Dec-2018)/total no. of live
births (1988–2018)*1 000 000], when calculated per year the
incidences were presented as rates. Prevalences were calculated
per million population [total no. of EB-patients alive at a time
point (31-Dec-2018)/total population at a time point (31-Dec-
2018)*1 000 000]. The number of live births, average life expec-
tancy of the Dutch population and population size of the
Netherlands were collected from the national Central Agency for
Statistics (https://opendata.cbs.nl/#/CBS/nl/). The epidemiologi-
cal data were analysed using SPSS 23.0 (SPSS Inc., Chicago, IL,
USA). There was no correction for multiplicity.
Results
Incidence and point-prevalence
From 1 January 1988 until 31 December 2018, 544 EB-patients
(358 families) were registered at our centre, of which 80 EB-pa-
tients (71 families; 14.7%) referred by specialists from foreign
countries. The remaining 464 EB-patients (287 families; 247 males
and 217 females) were based in the Netherlands, of which 346
patients were of Dutch descent (74.6%), 27 patients had a mixed
ethnic background (5.8%), 78 patients were immigrants (16.8%)
(n = 13 unknown, 2.8%). The incidence and point-prevalence of
EB in the Netherlands were calculated to be 41.3 per million live
births (5 830 469 live births, 1988–2018, StatLine, CBS, The
Hague, (South Holand), Netherlands) and 22.4 per million popu-
lation (17 282 163 total population, 31-Dec-2018, StatLine, CBS).
Overall, a genetic diagnosis was made in 420 patients (254
families; 90.5%). In 22 patients (18 families; 4.7%) no DNA was
available for mutation analysis. In another 22 patients (15 fami-
lies; 4.7%) no pathogenic mutation could be found (or just a
single pathogenic mutation in case of recessive EB) and hence
classified as genetically unsolved (Fig. 2b). However, the level of
blister formation could be established by IFM and TEM on avail-
able skin biopsies in most of these patients, and therefore the
major type of EB (n = 10 unknown).4 Dominant inheritance
was present in 304 patients (149 families; 65.5%) and recessive
inheritance in 160 patients (138 families; 34.5%). Only in 16
patients with recessive EB it remained uncertain whether the
parents were consanguineous or not.
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EB simplex In the Dutch-EB-Reg, EBS was most frequently
diagnosed (212 patients; 108 families; 45.7%) with an incidence
of 17.5 per million live births and a point-prevalence of 11.9 per
million population (Figs. 1 and 2a, Table 1). Dominant EBS was
more common than recessive EBS (191 patients; 94 families;
90.1% vs. 21 patients; 14 families; 9.9%). In 81.0% of the
patients with recessive EBS a homozygous mutation was found,
of which 52.9% associated with known parental consanguinity.
Mutation analysis implicated six genes in the EBS cohort. In
8.5% of the EBS-patients (n = 18) the causative gene could not
be discovered.
Junctional EB Junctional EB was diagnosed in 87 patients (72
families; 18.8%) with an incidence of 9.3 per million live births
and a point-prevalence of 2.1 per million population (Figs. 1
and 2a, Table 2). JEB was inherited autosomal recessively in
94.3% of the cases, of which 43.9% carried a homozygous muta-
tion (of which 58.3% associated with known parental consan-
guinity). In five patients (one family; 5.7%) a dominant form of
JEB was diagnosed, with a mutation in the ITGB4 gene.5 Six
genes were implicated in the pathogenesis of JEB in our cohort.
In 13.8% of the JEB-patients (n = 12) the diagnosis could not be
confirmed genetically.
Dystrophic EB Dystrophic EB was identified in 161 patients
(103 families; 34.7%) with recurrent and unique mutations in
the COL7A1 gene (Fig. 2a). An incidence of 14.1 per million live
births was calculated and a point-prevalence of 8.3 per million
population (Fig. 1, Table 3), with dominant DEB (DDEB) in
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Figure 1 Epidemiological outcomes of each major type of Epidermolysis Bullosa in the Netherlands for the time period 1988–2018,
n = 490. (a) Annual point-prevalence (per million population) of each major type of EB. (b) Annual incidence rates (per million live births).
Based on the Dutch Epidermolysis Bullosa Registry (Dutch-EB-Reg). DEB, dystrophic epidermolysis bullosa; EB, epidermolysis bullosa;
EBS, epidermolysis bullosa simplex; JEB, junctional epidermolysis bullosa.
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Figure 2 Distribution of the major types and genes involved in patients with Epidermolysis Bullosa in the Dutch Epidermolysis Bullosa
Registry for the time period 1988–2018, n = 464. (a) The total distribution and genes involved in the major EB types in the cohort of the
Dutch Epidermolysis Bullosa Registry (Dutch-EB-Reg). (b) The total distribution of the 14 genes involved in the Dutch Epidermolysis Bul-
losa Registry (Dutch-EB-Reg). Patients without mutation analysis performed were classified as ‘No DNA’; patients in which no pathogenic
mutation(s) could be found with mutation analysis were genetically classified as ‘Unsolved’.
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Epidemiology of EB in the Netherlands 7
53 patients (49 families; 32.9%), of which 35.8% carried a
homozygous mutation (94.7% of which had consanguineous
parents). In 7.5% of the DEB-patients (n = 12) the genotype
remained unknown.
Kindler EB Kindler EB was diagnosed in only four patients
(four families; 0.9%) with an incidence of 0.5 per million live
births and a point-prevalence of 0.2 per million population
(Figs. 1 and 2a, Table 4). In two patients with Kindler EB com-
pound heterozygous mutations in FERMT1 were found, in the
remaining two patients a clinical phenotype of Kindler EB was
present, but no pathogenic mutations could be found.
Epidemiological trends Based on the increasing number of reg-
istered EB-patients at our centre, the point-prevalence of EBS
and DEB has progressively increased over the years, while it pla-
teaued for JEB after an initial period of increase (Fig. 1a). On
the other hand, the yearly incidence rates showed a fluctuating
pattern (Fig. 1b).
EB and mortality
For the Netherlands, the average life expectancy was 81.8 years
(80.2 years for males and 83.3 years for females; 31-Dec-2018,
StatLine, CBS). During the investigated time period, 73 EB-pa-
tients (15.7%) in the Dutch-EB-Reg died, with an average age at
death (AAD) of 22.9 years (n = 72; SD: 31.0; n = 1 AAD
unknown). Of the 73 deceased EB-patients, 68 patients had a
recessive type of EB (47 JEB-patients, 16 DEB-patients, four
EBS-patients and one patient with Kindler EB) and five patients
a dominant type. A total of 53 patients with recessive EB
(77.9%) died as a direct consequence of known complications of
their EB; 72.6% of the total group of 73 deceased EB-patients. In
another six patients with recessive EB it was not possible to find
out whether their death was related to EB (8.8%). The remaining
nine patients with recessive EB died from EB-unrelated causes
(13.2%), which was also true for the five patients with dominant
EB (Table 5).
Mortality and EBS The average age of the alive EBS-patients in
the Dutch-EB-Reg was 34.3 years (n = 205; SD: 20.9) (31-Dec-
2018). Seven EBS-patients died during the investigated time per-
iod. Two patients with REBS-muscular dystrophy died at the age
of 43.7 and 46.0 years from cardiac failure. Two other patients
with REBS died at the age of 88.6 and 82.3 years, both consid-
ered being EB-unrelated. Three patients with dominant EBS died
at the age of 83.9, 67.3 and 23.8 years, all three considered being
EB-unrelated (Tables 1 and 5).
Mortality and JEB The average age of the alive JEB-patients in
the Dutch-EB-Reg was 33.0 years (n = 36; SD: 24.3) (31-Dec-
2018). A total of 47 JEB-patients died during the investigated
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Epidemiology of EB in the Netherlands 9
of JEB, an induced partus of a foetus with JEB-severe and a
patient with JEB-severe who died before 1988 but was captured
in the Dutch-EB-Reg during the investigated time period). For
JEB-pyloric atresia an AAD of 6 days was calculated (n = 6; SD:
2.3). All of whom died shortly after (cardio)respiratory problems
occurred and an abstaining policy was initiated. For JEB-severe
an AAD of 4.7 months (n = 29; SD: 6.5) was calculated, with an
exceptional outlier of 2.7 years, of which 26 patients (90%) died
within the first year of life. All patients with JEB-severe died
from EB-related complications, in order of frequency: failure to
thrive, respiratory insufficiency, infectious diseases and euthana-
sia (n = 1 unknown). For JEB-intermediate an AAD of
62.8 years (n = 11; SD: 25.4) was calculated. Those patients died
from: infectious diseases, euthanasia, metastatic squamous cell
carcinoma and EB-unrelated causes (n = 3 unknown) (Table 5).
Mortality and DEB The average age of the alive DEB-patients in
the Dutch-EB-Reg was 32.5 years (n = 143; SD: 23.0) (31-Dec-
2018), divided into an average age of 28.8 years for patients with
RDEB (n = 37; SD: 20.7) and 33.3 years for patients with DDEB
(n = 105; SD: 23.5). A total of 16 RDEB-patients died during
the investigated time period with an average AAD of 18.8 years
(SD: 16.7), further subdivided into an average AAD of 18.5 years
for RDEB-severe (n = 12; SD: 14.2). All RDEB-severe patients
died from EB-related complications: (metastatic) SCC, cardiac
failure, abstinence, euthanasia and sepsis (n = 1 unknown). Two
patients with RDEB-intermediate died during the investigated
time period at a young age from EB-related complications (AAD
8.4 months and 13.5 years). Two patients with RDEB-inversa
died during the investigated time period at the age of 8.0 and
57.3 years, from sepsis caused by chronic wounds and an EB-un-
related cause, respectively. Both patients with DDEB died from
EB-unrelated causes (AAD of 54.3 and 89.4 years; Table 5).
Mortality and Kindler EB One patient with Kindler EB died
during the investigated time period at the age of 67.7 years. The
cause of death remained unknown and therefore a potential cor-
relation with EB uncertain (Table 5). The other patients with
Kindler EB in the Dutch-EB-Reg were still alive, with an average
age of 13.8 years (n = 3; SD 9.3) (31-Dec-2018) (Table 4).
Discussion
Point-prevalence and incidence
This observational study presents epidemiological data on each
subtype of EB, extracted from the molecularly well-characterized
Dutch EB cohort in the Dutch-EB-Reg. In recent decades, sev-
eral epidemiological studies have been carried out in different
countries, reporting varying and sometimes inconclusive inci-
dences and prevalences (1.4–25.0 per million live births and
2.82–54.0 per million population, respectively), mostly based on
clinical features or molecular findings.6–19 In 90.5% of the EB-
patients in our cohort the diagnosis was genetically confirmed,
allowing accurate epidemiological analyses.
Both the calculated incidence of 41.3 per million live births
and point-prevalence of 22.4 per million population are high
compared to that reported in other countries, especially if the 26
patients with an EB-related skin fragility disorder would be
included (incidence of 44.9 per million live births; point-preva-
lence of 23.7 per million population) (Fig. 1, Table S1, Suppor-
ing Information). Over the years, increased knowledge,
advanced diagnostics and the reputation of our centre ensured
that an increasing number of EB-patients were seen at our centre
and captured in the Dutch-EB-Reg. The well-organized set-up in
a small and highly populated country, a robust healthcare system
with a good insurance policy and collaboration between special-
ists in the Netherlands ensured that most EB-patients were
referred to our centre (near-complete ascertainment), especially
those with severe subtypes of EB. Furthermore, being the only
national expertise centre for EB, all mutation analysis for EB
takes place in the UMCG. Therefore, we believe that the Dutch-
EB-Reg documents most of the EB-patients in the Dutch popu-
lation and our calculated figures come close to the actual num-
bers, even though they are higher than previously reported. Our
epidemiological data from the well-characterized Dutch EB
cohort thus indicate that EB may be more common than consid-
ered so far.
Risk of underestimation
Despite the expertise, knowledge and reputation of our centre, it
is assumed that still not every patient is referred to our national
centre, especially those with rather mild subtypes of EB. Those
patients may be treated by their general practitioner or local spe-
cialist, as earlier noticed by Horn et al.14 Besides, patients with
milder subtypes of EB who were born in the last few years are
expected to be registered in the following years, especially in case
of late-onset EB. Given the increasing number of registered
patients at our centre, the calculated figures might therefore still
be an underestimation.
Risk of misclassification
Another strength of our Dutch-EB-Reg is the long period of sys-
tematic data collection and longitudinal follow-up. During the
investigated time period, significant efforts were made to ade-
quately monitor the patient records and identify affected family
members. Despite the high level of expertise of our centre,
patients may have been misclassified. However, this number is
expected to be low, as in more than ninety per cent of the
patients the diagnosis was genetically confirmed (Fig. 2). In the
group of ‘Unsolved’ patients (n = 22) DNA analysis could not
provide a genetic diagnosis using the gold standard techniques
at the time of visiting our centre, neither with Sanger sequencing
nor with a panel of multiple EB-related genes. This may be due
to technical shortcomings, because the diagnosis of EB is
© 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
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incorrect, the presence of unusual mutations or mutations in
genes not known at the time of diagnostics, or mutations in as
yet unknown genes. Over the years developments have been
made in the registration and (sub)classification of the different
subtypes of EB. Although we have made attempts to correctly
convert the diagnoses from earlier consensus classifications to
the latest, these changes may have led to misclassifications and
fluctuating incidences and prevalences over time. This may be
particularly true for EBS, as the EB-related skin fragility disor-
ders were previously included in the EB spectrum as suprabasal
EBS (Fig. 1, Table S1, Supporing Information).1
Distribution of EB subtypes
The distribution of the subtypes of EB in the Dutch-EB-Reg
(EBS 45.7%, JEB 18.8%, DEB 34.7% (DDEB 23.1% and RDEB
11.4%) and Kindler EB 0.9%) differ from those reported in
other countries.6,7,16,20–22 Noteworthy, the population of JEB-
patients in the Dutch-EB-Reg is relatively higher than reported
in other countries. Worldwide variations in the population and
level of immigration (e.g. ethnic background, consanguineous
marriages, spectrum of mutations) may affect the epidemiology
and distribution of the subtypes of EB per region.20,23,24 During
the investigated time period, the Netherlands received an
increasing number of immigrants, especially from countries
where consanguineous marriages are more common than in the
native Dutch population (StatLine, CBS), which may have
resulted in an increasing number of patients with recessive, and
usually more severe, subtypes of EB.
Epidemiological trends
Over the years, the point-prevalence of EB, particularly EBS
and DEB, has progressively increased, representing an increas-
ing number of registered EB-patients at our centre. Interest-
ingly, the point-prevalence of JEB has reached a plateau since
2014. This may be attributed to the fact that the point-preva-
lence of JEB mainly consists of the non-lethal JEB-subtypes, as
the average life expectancy of patients with JEB-severe and
JEB-PA in the Dutch-EB-Reg was 4.7 months and 6 days,
respectively. Apparently, we have been able to register all other
JEB-patients in the Dutch-EB-Reg, in contrast to the relatively
milder and more common EBS and DDEB. Over the years, the
annual incidence rates showed a fluctuating pattern. The high
incidence of EBS in 2011 is likely a chance finding, all patients
were crosschecked.
EB and mortality
We found that 72.6% of the deceased EB-patients died as a
direct consequence of EB-related complications. JEB-patients
experienced the highest mortality rate, with an average survival
of 6 days for JEB-pyloric atresia (n = 6), 4.7 months for JEB-
severe (n = 29) and 62.8 years for JEB-intermediate (n = 12).
The AAD of patients with JEB-pyloric atresia and JEB-severe in
the Dutch-EB-Reg is low in comparison with other studies.10,25
The deceased patients with RDEB-severe had an average AAD of
18.5 years (n = 12), lower than the earlier reported 29.4 years
(n = 4) by Kho et al.10 However, due to the relatively small
number of deceased RDEB-patients in both the Dutch-EB-Reg
(with high standard deviations) and other studies, and the young
age of the alive RDEB-patients in the Dutch cohort, the question
is whether these data are comparable and representative for the
whole RDEB population. Future studies have to show whether
the life expectancy of RDEB-severe patients is truly that low.
Foreign EB-patients referred to our expertise centre
Since the referral of the first EB-patients from Belgium in 1997,
an increasing number of EB-patients were referred to our centre
by specialists from foreign countries for diagnostic testing and/
or to receive medical care. This demonstrates the need and value
of cross-country collaboration of healthcare professionals in the
diagnosis and care of EB-patients and rare diseases in general,
which might be impossible to organize for each disease in each
country individually, and from which the patients can only
benefit.
Conclusion
This study shows that EB might be more common than assumed
before and emphasizes the importance of thorough reporting
systems and registries worldwide, which is invaluable for the
design and execution of (upcoming) therapeutic trials. Besides,
it provides an insight into the extensive need for (specialized)
medical care of EB-patients.
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